Transparency Market Research (TMR) has published a new report titled, “Benzodiazepine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global benzodiazepine drugs market was valued at US $ 2,057.19 Mn in 2017. It is projected to expand at a CAGR of 2.7% between 2018 and 2026. The benzodiazepine drugs market is projected to expand during the forecast period owing to the rise in prevalence of anxiety, seizures, and increase in concerns among people about preventive measures for stress-related conditions.
Moreover, higher prescriptions for benzodiazepine drugs, as compared to other psychoactive drugs, and increase in rate of adoption of generic drugs are propelling the global benzodiazepine drugs market. North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals for benzodiazepine drugs in the region. Latin America and Asia Pacific are potential markets for benzodiazepine drugs. The market in Asia Pacific is projected to expand at a CAGR of 3.5% during the forecast period.
Rise in prevalence of anxiety and seizures is a major driver of the global benzodiazepine drugs market. Current lifestyle and urban life have made peoples’ lives more stressful, which leads to mental disorders such as depression, anxiety, panic, and maniac conditions. Psychoactive drugs, such as benzodiazepine, are required to relieve these conditions and attacks. For instance, according to WHO, in 2015, the total number of people living with anxiety disorders, globally, was 264 million. Similarly, higher number of prescriptions for benzodiazepines, as compared to other psychoactive drugs, and increase in rate of adoption of generic drugs are major drivers of the global benzodiazepine drugs market.
Request to View Sample of Report -
Alprazolam is expanding segment of the benzodiazepine drugs market. It is projected to account for 29.35% share of the market, and expand at a CAGR of 2.9%, during the forecast period. The segment is anticipated to reach a value of US$ 768.09 Mn by 2026. Extensive utilization of Alprazolam in anxiety and panic disorders and higher number of prescriptions of Alprazolam for these conditions are likely to drive the segment of the global market during the forecast period.
Anxiety was a dominant segment of the global benzodiazepine drugs market in 2017. It is expected to maintain its position during the forecast period. The segment is anticipated to reach a value of US$ 1,384.12 Mn by 2026. It is projected to account for 52.9% share of the market and expand at a CAGR of 3.1% during the forecast period. Benzodiazepine drugs are preferred to control the symptoms and general anxiety. Therefore, a rise in the prevalence of anxiety across the globe drives the segment. For instance, according to Anxiety and Depression Association of America (ADAA), around 40 million adults are affected every year with anxiety disorders, of which only 36.9% receive treatment.
Comments
Post a Comment